Clinical Trial Update: VX-222 + Telaprevir + Ribavirin for 12 or 16 Weeks in Treatment-Naive Subjects With Genotype 1a Hepatitis C [Phase 2]

View source ↗

Summary

Phase 2 study evaluating VX-222 in combination with telaprevir and ribavirin for genotype 1a chronic hepatitis C in treatment-naive patients; the trial comparin…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatitis C

Drugs mentioned

• Ribavirin (ribavirin)
• Telaprevir (telaprevir)
• VX-222 (VX-222)

Snippet

Sponsor: Vertex Pharmaceuticals Incorporated | Conditions: Chronic Hepatitis C Virus | Phase 2 | Status: COMPLETED